/PHGE
PHGE Stock - BiomX Inc.
Healthcare|BiotechnologyAMEX
$2.13+13.30%
+$0.25 (+13.30%) • Dec 19
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).38
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-6.1%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PHGE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.11 – $2.15
TARGET (TP)$2.00
STOP LOSS$1.96
RISK/REWARD1:-0.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.57
52W High$22.06
52W Low$1.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,803,000 | $-871,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-39,027,000 | $-27,685,000 | $-27,219,000 | $-35,462,000 | $-30,258,000 |
| Net Income | $-17,727,000 | $-26,169,000 | $-28,317,000 | $-36,226,000 | $-30,086,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-27.93 | $-96.90 | $-180.31 | $-264.67 | $-24.70 |
Company Overview
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PHGEBeat Rate
63%
Last 19 quarters
Avg Surprise
-48.8%
EPS vs Estimate
Beats / Misses
12/5
2 met exactly
Latest EPS
$-5.51
Q4 2025
EPS Surprise History
Q2 24
+27.3%
$-0.80vs$-1.10
Q2 24
-114.3%
$-1.50vs$-0.70
Q3 24
+158.3%
$0.70vs$-1.20
Q4 24
-61.7%
$-0.97vs$-0.60
Q1 25
+35.2%
$-1.07vs$-1.65
Q2 25
+21.4%
$-0.33vs$-0.42
Q3 25
+157.6%
$0.19vs$-0.33
Q4 25
+9.4%
$-5.51vs$-6.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-4.61 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-6.08 | $-5.51 | +9.4% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.33 | $0.19 | +157.6% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.42 | $-0.33 | +21.4% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-1.65 | $-1.07 | +35.2% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.60 | $-0.97 | -61.7% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-1.20 | $0.70 | +158.3% | ✓ BEAT |
Q2 2024 | May 20, 2024 | $-0.70 | $-1.50 | -114.3% | ✗ MISS |
Q2 2024 | Apr 3, 2024 | $-1.10 | $-0.80 | +27.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-1.10 | $-1.30 | -18.2% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-1.20 | $-1.20 | 0.0% | = MET |
Q2 2023 | May 15, 2023 | $-2.00 | $-2.00 | 0.0% | = MET |
Q1 2023 | Mar 29, 2023 | $-2.50 | $-2.00 | +20.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-2.40 | $-2.30 | +4.2% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-2.90 | $-2.50 | +13.8% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-3.20 | $-2.70 | +15.6% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.28 | $-3.60 | -1174.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-2.50 | $-3.70 | -48.0% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-3.70 | $-3.00 | +18.9% | ✓ BEAT |
Q2 2021 | May 24, 2021 | $-3.80 | $-3.50 | +7.9% | ✓ BEAT |
Latest News
BiomX Resolved to Approve And Authorize Filing Of Application To Commence Insolvency Proceedings
📉 NegativeBenzinga•Dec 11, 2025, 09:24 PM
PHGE shares are trading lower after the company discontinued its Phase 2b trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.
📉 NegativeBenzinga•Dec 8, 2025, 12:41 PM
BiomX Announces Discontinuation Of Ongoing Phase 2b Clinical Trial Of Nebulized Phage Therapy BX004 In Patients With CF Associated With Chronic Pseudomonas Aeruginosa Infections
📉 NegativeBenzinga•Dec 8, 2025, 12:35 PM
HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $26 Price Target
📈 PositiveBenzinga•Nov 26, 2025, 04:11 PM
BiomX Announced That The U.S. FDA Is Continuing Its Evaluation Of The Nebulizer Device Used For Drug Administration In The Co's Phase 2b Trial Of BX004 In Patients With Cystic Fibrosis; Following The DMC Review, The Study Protocol Will Be Updated, And Topline Results Are Now Expected In Q2 2026
➖ NeutralBenzinga•Nov 25, 2025, 09:44 PM
HC Wainwright & Co. Maintains Buy on BiomX, Raises Price Target to $26
📈 PositiveBenzinga•Nov 25, 2025, 11:54 AM
BiomX shares are trading lower after the company announced a 1-for-19 reverse stock split.
📉 NegativeBenzinga•Nov 17, 2025, 01:57 PM
BiomX Announces 1-For-19 Reverse Stock Split, Effective Nov. 25
📉 NegativeBenzinga•Nov 14, 2025, 09:35 PM
CORRECTION: BiomX Q3 EPS $(0.29) Beats $(0.32) Estimate. Cash & Equivalents $8.1M
📈 PositiveBenzinga•Nov 12, 2025, 01:36 PM
BiomX Q3 EPS $0.29 Beats $(0.32) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:32 PM
PHGE stock has given up its prior gain. BiomX shares were trading higher after the company announced FDA support to advance BX011 Phage Therapy for diabetic foot infections.
➖ NeutralBenzinga•Nov 4, 2025, 02:17 PM
BiomX shares are trading higher after the company announced FDA support to advance BX011 Phage Therapy for diabetic foot infections.
📈 PositiveBenzinga•Nov 4, 2025, 01:46 PM
BiomX Receives FDA Support To Advance BX011 Phage Therapy For Diabetic Foot Infections
📈 PositiveBenzinga•Nov 4, 2025, 01:41 PM
BiomX Releases Update For The FDA Clinical Hold For U.S. Portion Of Its BX004 Phase 2b Cystic Fibrosis Trial, Receiving Written Feedback From FDA Suggesting Potential Development Strategies For Bx004, Including Ways To Enrich Study Populations For Phase 3 Development
➖ NeutralBenzinga•Oct 17, 2025, 12:36 PM
HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $15 Price Target
📈 PositiveBenzinga•Aug 20, 2025, 10:38 AM•Also:
BiomX Says FDA Places Clinical Hold On Phase 2b Trial Of BX004 For Treatment Of Patients With Cystic Fibrosis
📉 NegativeBenzinga•Aug 19, 2025, 12:21 PM
BiomX Posts Q2 Loss With 14% Cost Drop
📉 NegativeThe Motley Fool•Aug 13, 2025, 06:52 PM
Frequently Asked Questions about PHGE
What is PHGE's current stock price?
BiomX Inc. (PHGE) is currently trading at $2.13 per share. The stock has moved +13.30% today.
What is the analyst price target for PHGE?
The average analyst price target for PHGE is $2.00, based on 1 analyst.
What sector is BiomX Inc. in?
BiomX Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is PHGE's market cap?
BiomX Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PHGE pay dividends?
No, BiomX Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
BRTX
BioRestorative Therapies, Inc.
$1.15
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
EDSA
Edesa Biotech, Inc.
$1.48
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
IMRN
Immuron Limited
$0.94
Mkt Cap: $0.0B
MPLT
MapLight Therapeutics, Inc.
$20.55
Mkt Cap: $0.0B
OSRH
OSR Holdings, Inc.
$0.65
Mkt Cap: $0.0B
PMN
ProMIS Neurosciences, Inc.
$8.55
Mkt Cap: $0.0B
TRAW
Traws Pharma, Inc.
$1.27
Mkt Cap: $0.0B
Explore stocks similar to PHGE for comparison